DCC4908 |
SS-thujaplicinol |
Inhibitor of the replication of herpes simplex viruses 1 and 2 (HSV-1 and HSV-2) |
|
DCC4909 |
Sstr3-agonist-5c |
Novel non-peptidic highly potent somatostatin receptor 3 (SSTR3) agonist |
|
DCC4910 |
Sstr3-antagonist-3a |
Novel potent sstr3 antagonist, showing to reduce glucose excursion in a mouse oGTT assay |
|
DCC4911 |
Sstr5a |
Novel somatostatin receptor subtype 5 antagonist, stimulating glucoseinduced GLP-1 secretion, reducing blood glucose in a gut- and GLP-1R-dependent manner |
|
DCC4912 |
St026567 |
Novel potent mast cell (MC) activator, promoting de novo synthesis of cytokines and inducing the release of eicosanoids from human and mouse MCs |
|
DCC4913 |
St029248 |
Novel potent mast cell (MC) activator, promoting de novo synthesis of cytokines and inducing the release of eicosanoids from human and mouse MCs |
|
DCC4914 |
St056083 |
Novel inhibitor of the c-di-AMP synthetase DNA integrity scanning protein (DisA) in vitro |
|
DCC4915 |
St101036 |
Novel potent mast cell (MC) activator, promoting de novo synthesis of cytokines and inducing the release of eicosanoids from human and mouse MCs |
|
DCC4916 |
st-1032 |
Novel histamine H3 receptor ligand |
|
DCC4917 |
St1237 |
Potent, direct, non-cytotoxic Arachidonate_5-lipoxygenase>5-lipoxygenase (5-LO) inhibitor |
|
DCC4918 |
St-161 |
Antiviral agent against LASV and a number of other viruses in the Arenaviridae family |
|
DCC4919 |
St-1703 |
Novel histamine H3 receptor ligand |
|
DCC4920 |
St-1892 |
Novel highly potent and soluble partial FXR agonist |
|
DCC4921 |
St-198 |
Seletive dopamine D3 receptors |
|
DCC4922 |
St-1992 |
Novel potent A 1 R/A 2A R/H 3 R multitargeting ligand (MTL) |
|
DCC4923 |
St-2001 |
Novel potent A 1 R/A 2A R/H 3 R multitargeting ligand (MTL) |
|
DCC4924 |
St-2262 |
Novel selective NaV1.7 inhibitor, blocking the extracellular vestibule of the channel with an IC50 of 72 nM and greater than 200-fold selectivity over off-target sodium channel isoforms, NaV1.1-1.6 and NaV1.8 |
|
DCC4925 |
St4070 |
Highly selective FAAH>fatty acid amide hydrolase (FAAH) inhibitor |
|
DCC4926 |
St7710aa1 |
Novel PARP-1 inhibitor, showing significant in vitro target inhibition and capability to substantially bypass the multidrug resistance mediated by Pgp |
|
DCC4927 |
Sta-9584 |
Novel tubulin-binding vascular disrupting agent (VDA) |
|
DCC4928 |
Stad-2 |
Cell permeable AKAP disruptor, selectively binding to PKA-RII and blocking the interaction of PKA-RI with AKAP |
|
DCC4929 |
Stalobacin I |
Novel Lipopeptide Antibiotic with Potent Antibacterial Activity against Multidrug-Resistant Bacteria |
|
DCC4930 |
Stanozolol [10418-03-8] |
Anabolic-androgenic steroid (AAS), acting as an agonist of the androgen receptor (AR) |
|
DCC4931 |
Stat3 -in-11 |
Novel STAT3 inhibitor, selectively inhibiting STAT3 phosphorylation and exhibiting potent antitumor activity |
|
DCC4932 |
stat3 Inhibitor 6 |
Novel inhibitor of STAT3 signaling pathway |
|
DCC4933 |
Stat3-in-13r |
Novel inhibitor of STAT3, targeting SH2 domain |
|
DCC4934 |
Stat3-in-3 |
Novel potent and selective inhibitor of STAT3 |
|
DCC4935 |
Stat3-in-a69 |
Novel inhibitor targeting the DNA-binding domain of STAT3, suppressing tumor growth, metastasis and STAT3 target gene expression in vivo |
|
DCC4936 |
Stat3-in-b9 |
Novel inhibitor of signal transducer and activator of transcription 3 (STAT3), inhibiting the proliferation of tumor cells harboring abnormal activation of STAT3, such as, MDA-MB-468, MDA-MB-231 and DU145 |
|
DCC4937 |
Stat5a-in-27 |
Novel cell-permeable selective STAT5a inhibitor prodrug, inhibiting tyrosine phosphorylation of STAT5a with selectivity over STAT5b in cultured human leukemia cells, and representing a valuable tool to define the non-redundant molecular functions of the t |
|